Jyong Biotech Ltd.

Listed Company

MENSCIK 0001954488NasdaqNon-AcceleratedEmerging GrowthPharmaceutical PreparationsE9KY

Business

Jyong Biotech Ltd. is a foreign private issuer in Pharmaceutical Preparations, headquartered in the Cayman Islands. Shares trade on Nasdaq under the ticker MENS.

Auto-generated from company profile

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	Dec 31, 2025 2025-12-31	Dec 31, 2024 2024-12-31	Dec 31, 2023 2023-12-31
Operating expenses	—	—	—
Research and development	813,000	927,000	1
Selling and marketing	45,000	44,000	47,000
General and administrative	2	1	2
Total operating expenses	3	2	3
Loss from operations	−3	−2	−3
Other incomes (expenses):	—	—	—
Interest income	610,000	7,000	56,000
Interest expenses	3	1	757,000
Other (losses) gains, net	−135,000	65,000	−902,000
Total other expenses, net	−2	−963,000	−2
Loss before income tax	−5	−3	−4
Income tax expense	—	—	—
Net loss	−5	−3	−4
Other comprehensive (loss) income	—	—	—
Foreign currency translation adjustments, net of nil tax	−439,000	573,000	−42,000
Total comprehensive loss	−5	−2	−4
Net loss per share:	—	—	—
Basic (in Dollars per share)	−0.06	−0.04	−0.06
Diluted (in Dollars per share)	−0.06	−0.04	−0.06
Weighted average shares outstanding (in thousands):	—	—	—
Basic (in Shares)	73	72	72
Diluted (in Shares)	73	72	72

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	Dec 31, 2025 2025-12-31	Dec 31, 2024 2024-12-31
Current Assets	—	—
Cash	1	98,000
Restricted cash	3,000	3,000
Prepayments and other current assets	854,000	105,000
Loan receivable from shareholder	14	—
Total current assets	16	206,000
Property and equipment, net	3	3
Operating right-of-use assets	66,000	137,000
Deferred offering costs	—	934,000
Restricted asset	2	2
Other non-current assets	6,000	6,000
Total non-current assets	5	6
TOTAL ASSETS	21	6
Current liabilities	—	—
Short-term bank loans	8	7
Notes and accounts payable	2,000	3,000
Accrued expenses	1	1
Accrued expenses due to related parties	281,000	147,000
Current portion of long-term bank loans	571,000	57,000
Operating lease liabilities due to related parties-current	81,000	159,000
Accrued liabilities - guarantee obligation	22	—
Other current liabilities	3	3
Other current liabilities due to related parties	68,000	41,000
Total current liabilities	35	12
Long-term loan from related parties	12	11
Long-term loan from third parties	2	3
Long-term bank loans, net of current portion	2	2
Operating lease liabilities due to related parties – non-current	26,000	16,000
Other non-current liabilities	60,000	58,000
Other non-current liabilities due to related parties	628,000	628,000
Guarantee liabilities	—	19
Total non-current liabilities	11	31
TOTAL LIABILITIES	46	43
Commitments and contingencies (Note 18)	—	—
Shareholders’ deficit	—	—
Ordinary shares, $0.00001 par value; 5,000,000 thousand shares authorized; 73,361 thousand and 76,028 thousand shares issued and outstanding as of December 31, 2024 and 2025, respectively	1,000	1,000
Additional paid-in capital	29	12
Treasury shares, 1,794 thousand shares as of December 31, 2024 and 2025, respectively	16	16
Accumulated deficit	−38	−33
Accumulated other comprehensive income	682,000	1
Total shareholders’ deficit	−25	−37
TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT	21	6

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	Dec 31, 2025 2025-12-31	Dec 31, 2024 2024-12-31	Dec 31, 2023 2023-12-31
Cash flows from operating activities	—	—	—
Net loss	−5	−3	−4
Adjustments to reconcile net loss to net cash used in operating activities:	—	—	—
Depreciation	100,000	120,000	127,000
Noncash operating lease expenses	176,000	170,000	175,000
Fair value changes in the guarantee liabilities	−19	591,000	379,000
Gain on disposal of short-term investments	3,000	—	—
Prepayments and other current assets	749,000	8,000	2,000
Notes and accounts payable	−1,000	1,000	−2,000
Accrued liabilities – guarantee obligation	22	—	0
Accrued expenses	−159,000	76,000	254,000
Accrued expenses due to related parties	134,000	92,000	42,000
Operating lease liabilities due to related parties	−130,000	−124,000	−128,000
Other current liabilities	10,000	−2	878,000
Other current liabilities due to related parties	27,000	20,000	17,000
Other non-current liabilities	—	−1,000	59,000
Net cash used in operating activities	−3	−4	−3
Cash flows from investing activities	—	—	—
Purchases of short-term investments	17	—	—
Proceeds from disposal of short-term investments	17	—	—
Proceeds from maturity of time deposits	—	—	95,000
Loan to a shareholder	−15	—	—
Repayment from shareholder	1	—	—
Net cash provided by (used in) investing activities	−14	—	95,000
Cash flows from financing activities	—	—	—
Payments of deferred offering costs	114,000	213,000	445,000
Proceeds from short-term bank loans	23	9	10
Repayment of short-term bank loans	23	9	9
Proceeds from issuance of ordinary shares	18	—	—
Proceeds of loan from related parties	1	2	2
Repayments of loan from related parties	−800,000	—	−120,000
Repayment of loan from third party	700,000	—	—
Repayments of long-term bank loans	60,000	71,000	123,000
Net cash provided by financing activities	18	2	2
Effects of exchange rate changes on cash and restricted cash	−8,000	−7,000	−54,000
NET (DECREASE)INCREASE IN CASH AND RESTRICTED CASH	1	−2	−532,000
TOTAL CASH AND RESTRICTED CASH	—	—	—
TOTAL CASH AND RESTRICTED CASH	—	—	—
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION	—	—	—
Income taxes paid	—	—	—
Interest paid	337,000	223,000	104,000
Reconciliation to amount on consolidated balance sheets	—	—	—
Cash	—	—	—
Restricted cash	—	—	—
TOTAL CASH AND RESTRICTED CASH	—	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro